Evidence map›Paper›PMID 37734129›Full record

ArticleJournal of infection and public health2023

High prevalence of hepatitis delta virus among people with hepatitis B virus and HIV coinfection in Botswana.

Kabo Baruti, Bonolo B Phinius, Basetsana Phakedi, Gorata Mpebe, Wonderful Choga, Lynnette Bhebhe, Graceful Mulenga, Natasha O Moraka, Tsholofelo Ratsoma, Molly Pretorius-Holme and 7 more

Open access · goldAbstract read
In one paragraph

Article in Journal of infection and public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 2 countries.

Kabo BarutiResearch laboratory, Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana; Department of Biological Sciences, Faculty of Science, University of Botswana, Gaborone, Botswana.
Bonolo B PhiniusResearch laboratory, Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana; School of Allied Health Professions, Faculty of Health Sciences, University of Botswana, Gaborone, Botswana.
Basetsana PhakediResearch laboratory, Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Gorata MpebeResearch laboratory, Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Wonderful ChogaResearch laboratory, Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana; School of Allied Health Professions, Faculty of Health Sciences, University of Botswana, Gaborone, Botswana.
Lynnette BhebheResearch laboratory, Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Graceful MulengaResearch laboratory, Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Natasha O MorakaResearch laboratory, Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana; School of Allied Health Professions, Faculty of Health Sciences, University of Botswana, Gaborone, Botswana.
Tsholofelo RatsomaResearch laboratory, Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Molly Pretorius-HolmeDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston MA, United States.
Joseph MakhemaResearch laboratory, Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston MA, United States.
Roger ShapiroResearch laboratory, Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston MA, United States.
Shahin LockmanResearch laboratory, Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston MA, United States.
Sikhulile MoyoResearch laboratory, Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston MA, United States.
Mosimanegape JongmanDepartment of Biological Sciences, Faculty of Science, University of Botswana, Gaborone, Botswana.
Motswedi AndersonResearch laboratory, Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Simani GaseitsiweResearch laboratory, Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston MA, United States. Electronic address: sgaseitsiwe@gmail.com.
Botswana International University of Science and Technology · BWHarvard University · USUniversity of Botswana · BW

Funding

Training in HIV Genomics, Treatment, and Cure Research in BotswanaD43TW009610 · FIC · THE BOTSWANA HARVARD HEALTH PARTNERSHIP · PI SHAHIN LOCKMAN, Joseph Moeketsi Makhema · 2013 to 2026
$4.4M
Viral Diversity an Innovative Biomarker for Refining Estimates of HIV IncidenceK43TW012350 · FIC · THE BOTSWANA HARVARD HEALTH PARTNERSHIP · PI Sikhulile Moyo · 2022 to 2026
$682k
FIC NIH HHS D43 TW009610FIC NIH HHS K43 TW012350
6 · The paper itself

Abstract

backgroundApproximately 15-20 million people worldwide are infected with hepatitis delta virus (HDV), which is approximately 5 % of people with chronic hepatitis B virus (HBV). Sub-Saharan Africa has high HDV prevalence, leading to worse clinical outcomes among people who are HIV/HBV/HDV tri-infected. There are limited data on HDV prevalence among people with HIV (PWH) who are HBV-infected and uninfected in Botswana. We, therefore, determined HDV prevalence among PWH in Botswana.

methodsThis was a retrospective cross-sectional study utilizing archived plasma samples from PWH with results for HBV markers such as hepatitis B surface antigen (HBsAg), hepatitis B core antibody (anti-HBc), immunoglobulin M antibody to hepatitis B core antigen (IgM anti-HBc) and hepatitis B e antigen (HBeAg). Samples were categorized according to their HBsAg status and screened for anti-HDV antibodies. Total nucleic acid was extracted from samples with a single positive anti-HDV result, and HDV ribonucleic acid (RNA) load was quantified using the Altona Diagnostic RealStar® HDV RT-PCR kit. Statistical analysis was performed using STATA version 14.0 where p-values < 0.05 were considered statistically significant.

resultsThe study cohort (n = 478) included both HBsAg positive (44 %) and negative (56 %) participants, with a median age of 42 [IQR; 41-43]. Anti-HDV prevalence of (15/211) [7.1 %, 95 % CI: 4.4 - 11.4] was recorded among HBsAg positive participants, all of whom were IgM anti-HBc negative, while 5/6 participants were HBeAg negative. HDV RNA load was detected in 11/12 (92 %) anti-HDV-positive participants. No HDV prevalence was recorded among participants who were HBsAg negative, therefore, the overall HDV prevalence was (15/478) [3.1 %, 95 % CI: 1.9 - 5.1]. HIV viral load suppression was statistically insignificant, irrespective of HDV status.

conclusionsWe report high HDV prevalence among HBsAg-positive PWH in Botswana. Most HDV-positive participants had active HDV infection, therefore, we recommend HDV screening in this cohort to guide their clinical care.

Indexed as

CoinfectionHepatitis BHepatitis B, ChronicHIV InfectionsBotswanaCross-Sectional StudiesHepatitis B AntibodiesHepatitis B e AntigensHepatitis B Surface AntigensHepatitis B virusHepatitis Delta VirusHumansImmunoglobulin MPrevalenceRetrospective StudiesRNAHepatitis B AntibodiesHepatitis B e AntigensHepatitis B Surface AntigensImmunoglobulin MRNABotswanaHepatitis delta virusPeople with HIVPrevalence

Identifiers

PMID37734129
PMCPMC10589822
OpenAlexW4386020816

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.